March 18th 2025
Prior to approval on February 14, 2025, the only FDA approved vaccine for chikungunya protection was indicated for 18 years and up.
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Medical boards feel the pressure to let it go when doctors spread COVID-19 misinformation
February 22nd 2022Stopping some doctors from sharing unsound medical advice has proved challenging. Even defining misinformation has been difficult. And during the pandemic, resistance from some state legislatures is complicating the effort.
COVID-19 vaccine exposure in utero not linked to adverse neonatal outcomes
February 11th 2022The safety of the Pfizer/BioNTech COVID-19 vaccine in pregnant women, for both mother and baby, has been dependent on observation during the rollout. A large population trial provides further support for the vaccine’s safety.
Does maternal history of cervical cancer/biopsy impact HPV vaccine rate in kids?
December 16th 2021For mothers who have an experience with human papillomavirus (HPV) vaccine preventable outcomes such as a cervical biopsy or cancer, would this history make them more likely to have their child receive this vaccine? It may seem likely, but a new study raises questions about this belief.
Trial examines safety and efficacy of HPV vaccine in young cancer survivors
November 22nd 2021Surviving a bout of cancer early in life puts children and teenagers at risk of cancers linked to human papillomavirus (HPV). A phase 2 trial examined how effective a 3-dose series was in providing protection.